Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.09.2022 | Case report

Dexamethasone/ixazomib/lenalidomide

Pneumonia: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Sasaki M, et al. EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere 6 (Suppl. 3): 3495-3496 abstr. PB2019, Jun 2022. Available from: URL: http://doi.org/10.1097/01.HS9.0000852292.38263.b8 [abstract] Sasaki M, et al. EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere 6 (Suppl. 3): 3495-3496 abstr. PB2019, Jun 2022. Available from: URL: http://​doi.​org/​10.​1097/​01.​HS9.​0000852292.​38263.​b8 [abstract]
Metadaten
Titel
Dexamethasone/ixazomib/lenalidomide
Pneumonia: case report
Publikationsdatum
01.09.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-23985-0

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Adalimumab

Case report

Sotalol

Case report

Multiple drugs

Case report

Iohexol

Case report

Multiple drugs